{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T15:09:03Z","timestamp":1795014543192,"version":"4.9.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We describe 1000 patients with essential thrombocythemia seen at the Mayo Clinic between 1967 and 2023: median age 58 years (18\u201390), females 63%,\n                    <jats:italic>JAK2<\/jats:italic>\n                    \/\n                    <jats:italic>CALR<\/jats:italic>\n                    \/\n                    <jats:italic>MPL<\/jats:italic>\n                    -mutated 62%\/27%\/3%, triple-negative (TN) 8%, extreme thrombocytosis (ExT; platelets \u22651000\u2009\u00d7\u200910\n                    <jats:sup>9<\/jats:sup>\n                    \/L) 26%, leukocytosis (leukocyte count &gt;11\u2009\u00d7\u200910\n                    <jats:sup>9<\/jats:sup>\n                    \/L) 20%, and abnormal karyotype 6%.\n                    <jats:italic>JAK2<\/jats:italic>\n                    -mutated patients were older (median 71 years), and\n                    <jats:italic>CALR<\/jats:italic>\n                    mutated (52 years), and TN (50 years) younger (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.01). Female gender clustered with TN (73%) and\n                    <jats:italic>JAK2<\/jats:italic>\n                    (69%) vs.\n                    <jats:italic>CALR<\/jats:italic>\n                    \/\n                    <jats:italic>MPL<\/jats:italic>\n                    (49%\/47%) mutations (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.01). ExT clustered with\n                    <jats:italic>CALR<\/jats:italic>\n                    (type-2 more than type-1) and TN and leukocytosis with\n                    <jats:italic>JAK2<\/jats:italic>\n                    mutation (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.01). In multivariable analysis, risk factors for overall survival were older age (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.01), male gender (HR 1.8), absolute neutrophil count (ANC)\u2009\u2265\u20098\u2009\u00d7\u200910\n                    <jats:sup>9<\/jats:sup>\n                    \/L (HR 1.6), absolute lymphocyte count (ALC)\u2009&lt;\u20091.7\u2009\u00d7\u200910\n                    <jats:sup>9<\/jats:sup>\n                    \/L (HR 1.5), hypertension (HR 1.7), and arterial thrombosis history (HR 1.7); for leukemia-free survival, ExT (HR 2.3) and abnormal karyotype (HR 3.1); for myelofibrosis-free survival, ANC\u2009\u2265\u20098\u2009\u00d7\u200910\n                    <jats:sup>9<\/jats:sup>\n                    \/L (HR 2.3) and\n                    <jats:italic>MPL<\/jats:italic>\n                    mutation (HR 3.9); for arterial thrombosis-free survival, age \u226560 years (HR 1.9), male gender (HR 1.6), arterial thrombosis history (HR 1.7), hypertension (HR 1.7), and\n                    <jats:italic>JAK2<\/jats:italic>\n                    mutation (HR 1.8); for venous thrombosis-free survival, male gender (HR 1.8) and venous thrombosis history (HR 3.0). Associations between ExT and leukemic transformation and between ANC and fibrotic progression were limited to\n                    <jats:italic>JAK2<\/jats:italic>\n                    -mutated cases. Aspirin therapy appeared to mitigate both arterial (HR 0.4) and venous (HR 0.4) thrombosis risk. HR-based risk models delineated patients with median survivals ranging from 10 years to not reached and 20-year leukemia\/myelofibrosis incidences from 3%\/21% to 12.8%\/49%. The current study provides both novel and confirmatory observations of essential thrombocythemia.\n                  <\/jats:p>","DOI":"10.1038\/s41408-023-00972-x","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T03:02:34Z","timestamp":1705546954000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["One thousand patients with essential thrombocythemia: the Mayo Clinic experience"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-6172","authenticated-orcid":false,"given":"Naseema","family":"Gangat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6026-4073","authenticated-orcid":false,"given":"Omer","family":"Karrar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0824-3715","authenticated-orcid":false,"given":"Aref","family":"Al-Kali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2730-8593","authenticated-orcid":false,"given":"Kebede H.","family":"Begna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra P.","family":"Wolanskyj-Spinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Animesh","family":"Pardanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis A.","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhett P.","family":"Ketterling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4605-3821","authenticated-orcid":false,"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,18]]},"reference":[{"key":"972_CR1","doi-asserted-by":"crossref","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemia: integrating morphological, clinical, and genomic data. Blood. 2022;140:1200\u201328.","DOI":"10.1182\/blood.2022015850"},{"key":"972_CR2","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/ajh.26008","volume":"95","author":"A Tefferi","year":"2020","unstructured":"Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95:1599\u2013613.","journal-title":"Am J Hematol"},{"key":"972_CR3","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1056\/NEJMcp1816082","volume":"381","author":"A Tefferi","year":"2019","unstructured":"Tefferi A, Pardanani A. Essential thrombocythemia. N. Engl J Med. 2019;381:2135\u201344.","journal-title":"N. Engl J Med"},{"key":"972_CR4","doi-asserted-by":"publisher","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","volume":"117","author":"A Carobbio","year":"2011","unstructured":"Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011;117:5857\u20139.","journal-title":"Blood"},{"key":"972_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.95","volume":"5","author":"S Cerquozzi","year":"2015","unstructured":"Cerquozzi S, Tefferi A. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer J. 2015;5:e366.","journal-title":"Blood Cancer J"},{"key":"972_CR6","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/leu.2011.258","volume":"26","author":"G Finazzi","year":"2012","unstructured":"Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, et al. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia. 2012;26:716\u20139.","journal-title":"Leukemia"},{"key":"972_CR7","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.mayocp.2018.08.022","volume":"94","author":"N Szuber","year":"2019","unstructured":"Szuber N, Mudireddy M, Nicolosi M, Penna D, Vallapureddy RR, Lasho TL, et al. 3023 Mayo Clinic patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups. Mayo Clin Proc. 2019;94:599\u2013610.","journal-title":"Mayo Clin Proc"},{"key":"972_CR8","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1002\/ajh.25270","volume":"93","author":"N Szuber","year":"2018","unstructured":"Szuber N, Vallapureddy RR, Penna D, Lasho TL, Finke C, Hanson CA, et al. Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger. Am J Hematol. 2018;93:1474\u201384.","journal-title":"Am J Hematol"},{"key":"972_CR9","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","volume":"124","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124:2507\u201313.","journal-title":"Blood"},{"key":"972_CR10","doi-asserted-by":"crossref","unstructured":"Tefferi A, Loscocco GG, Farrukh F, Szuber N, Mannelli F, Pardanani A, et al. A globally applicable \u201ctriple A\u201d risk model for essential thrombocythemia based on age, absolute neutrophil count, and absolute lymphocyte count. Am J Hematol. 2023;98:1829\u201337.","DOI":"10.1002\/ajh.27079"},{"key":"972_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00639-z","volume":"12","author":"N Gangat","year":"2022","unstructured":"Gangat N, Jadoon Y, Szuber N, Hanson CA, Wolanskyj-Spinner AP, Ketterling RP, et al. Cytogenetic abnormalities in essential thrombocythemia: clinical and molecular correlates and prognostic relevance in 809 informative cases. Blood Cancer J. 2022;12:44.","journal-title":"Blood Cancer J"},{"key":"972_CR12","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/bjh.16380","volume":"189","author":"A Tefferi","year":"2020","unstructured":"Tefferi A, Guglielmelli P, Lasho TL, Coltro G, Finke CM, Loscocco GG, et al. Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. Br J Haematol. 2020;189:291\u2013302.","journal-title":"Br J Haematol"},{"key":"972_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.94","volume":"5","author":"T Barbui","year":"2015","unstructured":"Barbui T, Vannucchi AM, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, et al. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J. 2015;5:e369.","journal-title":"Blood Cancer J"},{"key":"972_CR14","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/ajh.24293","volume":"91","author":"M Haider","year":"2016","unstructured":"Haider M, Gangat N, Lasho T, Abou Hussein AK, Elala YC, Hanson C, et al. Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients. Am J Hematol. 2016;91:390\u20134.","journal-title":"Am J Hematol"},{"key":"972_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","volume":"87","author":"A Tefferi","year":"2012","unstructured":"Tefferi A, Lasho TL, Jimma T, Finke CM, Gangat N, Vaidya R, et al. One thousand patients with primary myelofibrosis: the mayo clinic experience. Mayo Clin Proc. 2012;87:25\u201333.","journal-title":"Mayo Clin Proc"},{"key":"972_CR16","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"972_CR17","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/ajh.23585","volume":"89","author":"T Barbui","year":"2014","unstructured":"Barbui T, Thiele J, Gisslinger H, Finazzi G, Carobbio A, Rumi E, et al. Masked polycythemia vera (mPV): results of an international study. Am J Hematol. 2014;89:52\u20134.","journal-title":"Am J Hematol"},{"key":"972_CR18","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29:3179\u201384.","journal-title":"J Clin Oncol"},{"key":"972_CR19","doi-asserted-by":"publisher","first-page":"E121","DOI":"10.1002\/ajh.23743","volume":"89","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Wassie EA, Guglielmelli P, Gangat N, Belachew AA, Lasho TL, et al. Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol. 2014;89:E121\u2013124.","journal-title":"Am J Hematol"},{"key":"972_CR20","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/ajh.24338","volume":"91","author":"YC Elala","year":"2016","unstructured":"Elala YC, Lasho TL, Gangat N, Finke C, Barraco D, Haider M, et al. Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia. Am J Hematol. 2016;91:503\u20136.","journal-title":"Am J Hematol"},{"key":"972_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.98","volume":"6","author":"M Haider","year":"2016","unstructured":"Haider M, Elala YC, Gangat N, Hanson CA, Tefferi A. MPL mutations and palpable splenomegaly are independent risk factors for fibrotic progression in essential thrombocythemia. Blood Cancer J. 2016;6:e487.","journal-title":"Blood Cancer J"},{"key":"972_CR22","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1002\/ajh.26332","volume":"96","author":"GG Loscocco","year":"2021","unstructured":"Loscocco GG, Guglielmelli P, Gangat N, Rossi E, Mannarelli C, Betti S, et al. Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: a multicenter study involving 1607 patients. Am J Hematol. 2021;96:1472\u201380.","journal-title":"Am J Hematol"},{"key":"972_CR23","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1002\/ajh.24882","volume":"92","author":"A Tefferi","year":"2017","unstructured":"Tefferi A, Betti S, Barraco D, Mudireddy M, Shah S, Hanson CA, et al. Gender and survival in essential thrombocythemia: a two-center study of 1494 patients. Am J Hematol. 2017;92:1193\u20137.","journal-title":"Am J Hematol"},{"key":"972_CR24","doi-asserted-by":"publisher","first-page":"E93","DOI":"10.1002\/ajh.26114","volume":"96","author":"N Gangat","year":"2021","unstructured":"Gangat N, Szuber N, Jawaid T, Hanson CA, Pardanani A, Tefferi A. Young platelet millionaires with essential thrombocythemia. Am J Hematol. 2021;96:E93\u20135.","journal-title":"Am J Hematol"},{"key":"972_CR25","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1111\/jth.15834","volume":"20","author":"N Gangat","year":"2022","unstructured":"Gangat N, Singh A, Szuber N, Begna K, Elliott M, Wolanskyj-Spinner A, et al. Site-specific venous thrombosis in essential thrombocythemia: Impact on subsequent vascular events and survival. J Thromb Haemost. 2022;20:2439\u201343.","journal-title":"J Thromb Haemost"},{"key":"972_CR26","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1182\/bloodadvances.2022007023","volume":"6","author":"N Gangat","year":"2022","unstructured":"Gangat N, Szuber N, Jadoon Y, Farrukh F, Begna K, Elliott MA, et al. 1.5 million platelet count limit at essential thrombocythemia diagnosis: correlations and relevance to vascular events. Blood Adv. 2022;6:3835\u201339.","journal-title":"Blood Adv"},{"key":"972_CR27","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/bjh.18906","volume":"202","author":"OS Karrar","year":"2023","unstructured":"Karrar OS, Abdelmagid M, Vannucchi AM, Barbui T, Tefferi A, Gangat N. ABO blood group type and risk of venous thrombosis in essential thrombocythemia. Br J Haematol. 2023;202:699\u2013703.","journal-title":"Br J Haematol"},{"key":"972_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00470-y","volume":"11","author":"P Guglielmelli","year":"2021","unstructured":"Guglielmelli P, Gangat N, Coltro G, Lasho TL, Loscocco GG, Finke CM, et al. Mutations and thrombosis in essential thrombocythemia. Blood Cancer J. 2021;11:77.","journal-title":"Blood Cancer J"},{"key":"972_CR29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","volume":"1","author":"A Tefferi","year":"2016","unstructured":"Tefferi A, Lasho TL, Guglielmelli P, Finke CM, Rotunno G, Elala Y, et al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Adv. 2016;1:21\u201330.","journal-title":"Blood Adv"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00972-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00972-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00972-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T15:02:04Z","timestamp":1705590124000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00972-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,18]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["972"],"URL":"https:\/\/doi.org\/10.1038\/s41408-023-00972-x","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,18]]},"assertion":[{"value":"14 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11"}}